Evolving strategies for the use of combination therapy in hypertension
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Two thirds of patients with hypertension require more than one drug to achieve goal blood pressure. Rational antihypertensive drug combinations are based on their ability to produce additive blood pressure reduction and reduce the incidence of dose-dependent side effects. Some combinations exhibit side-effect neutralization in which side effects associated with one drug are neutralized by a second agent. Fixed-dose combinations improve adherence by reducing the number of pills and simplifying the treatment regimen. Because volume overload is common, low-dose diuretics are often included in drug combinations. Combinations of diuretics with potassium-sparing diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and ß-blockers are useful in treating large segments of the hypertensive population. Combinations of calcium channel blockers and angiotensin converting enzyme inhibitors are also effective and reduce the incidence of calcium blocker-related edema. Combinations of agents affecting the reninangiotensin system by different mechanisms are currently the subject of active investigation.
- Hyman DJ, Pavlik VN: Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001, 345:479–486. CrossRef
- Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351:1755–1762. In this important study, the authors aggressively pursue goal diastolic blood pressures of 90, 85, and 80 mm Hg. In so doing, they provide convincing data regarding the necessity of combination therapy in most hypertensive patients. CrossRef
- BakrisGL: Maximizing cardiorenal benefit in the management of hypertension: achieve blood pressure goals. J Clin Hypertens 1999, 1:141–147.
- Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of SHEP. JAMA 1991, 265:3255–3264. CrossRef
- Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:995–1003. This important study is among the first to aggressively pursue control of both systolic and diastolic blood pressure. To achieve treatment goals, combination therapy was needed in more than 90% of patients. CrossRef
- Materson BJ, Reda DJ, Cushman WG, et al.: Results of combination anti-hypertensive therapy after failure of each of the components. J Hum Hypertens 1995, 9:791–796.
- Siscovick DS, Raghunathan TE, Psaty BM, et al.: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994, 330:1852–1857. CrossRef
- Frishman WH, Bryzinki BS, Coulson LR, et al.: A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med 1994, 154:1461–1468. CrossRef
- The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153. CrossRef
- Lewis EJ, Hunsicker LG, Clark WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860. CrossRef
- Veterans Administration Cooperative Study Group on Antihypertensive Agents: Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984, 144:1497–1953. CrossRef
- Agodoa LY, Appel L, Bakris GL, et al.: African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719–2728. CrossRef
- Flack JM, Saunders E, Gradman AH, et al.: Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Amerians with mild to moderate hypertension. Clin Ther 2001, 23:1193–1208. CrossRef
- Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869. CrossRef
- Gradman AH, Cutler NR, Davis PJ, et al.: Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol 1997, 79:431–435. This clinical trial demonstrates the use of factorial design to scientifically determine correct combination dosages, and also provides an excellent example of side-effect neutralization when ACE inhibitors and calcium channel blockers are combined. CrossRef
- Bakris GL, Weir MR, DeQuattro V, et al.: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283–1289. CrossRef
- Mogenson CE, Neldam S, Tikkanen I, et al.: Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440–1444. CrossRef
- Williams ES, Miller JM: Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. J Am Coll Cardiol 2002, 40:1–18. CrossRef
- Buckalew V, Altamirano J, Epstein M, et al.: Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction [abstract]. J Am Coll Cardiol 2002, 39:249A.
- Evolving strategies for the use of combination therapy in hypertension
Current Hypertension Reports
Volume 4, Issue 5 , pp 343-349
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Industry Sectors